BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16701982)

  • 1. Antifungal drug resistance: limited data, dramatic impact?
    Rogers TR
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():7-11. PubMed ID: 16701982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal resistance in pathogenic fungi.
    Perea S; Patterson TF
    Clin Infect Dis; 2002 Nov; 35(9):1073-80. PubMed ID: 12384841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to antifungal agents in the critical care setting: problems and perspectives.
    Martins MD; Rex JH
    New Horiz; 1996 Aug; 4(3):338-44. PubMed ID: 8856751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluconazole resistance in Candida albicans: a review of mechanisms.
    Casalinuovo IA; Di Francesco P; Garaci E
    Eur Rev Med Pharmacol Sci; 2004; 8(2):69-77. PubMed ID: 15267120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
    Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
    Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
    J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on echinocandin antifungals.
    Kauffman CA; Carver PL
    Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida endophthalmitis: focus on current and future antifungal treatment options.
    Khan FA; Slain D; Khakoo RA
    Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
    Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
    J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological advances in the treatment of invasive candidiasis.
    Deck DH; Guglielmo BJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in antifungal chemotherapy.
    Petrikkos G; Skiada A
    Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
    Ghannoum MA; Kim HG; Long L
    J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical consequences of resistant Candida infections in intensive care.
    Montravers P; Jabbour K
    Int J Antimicrob Agents; 2006 Jan; 27(1):1-6. PubMed ID: 16343859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis].
    Viudes A; Cantón E; Pemán J; López-Ribot JL; Gobernado M
    Rev Esp Quimioter; 2002 Mar; 15(1):32-42. PubMed ID: 12582435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to echinocandins in Candida albicans: case report and review.
    Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
    J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug resistance in the treatment of invasive fungal infections].
    Nordøy I; Gaustad P
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on fungal infections.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Jul; 3(7):27-32. PubMed ID: 11364470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
    Chamilos G; Kontoyiannis DP
    Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.